Biomarker Bench
Some entries on this page are pending research verification.

Biomarker

APOB (Apolipoprotein B)

Counts the actual number of atherogenic particles in your blood. Better than LDL.

Unit
mg/dL
Optimal range
<60 (aggressive), <80 (standard)
Test methods
serum APOB immunoassay · Sniderman estimation from lipid panel

Why APOB matters

APOB counts the actual atherogenic particles in your blood. Every LDL, VLDL, IDL, and Lp(a) particle carries exactly one APOB molecule, so the serum APOB concentration is a direct particle count. LDL-C measures the cholesterol cargo inside those particles. Cargo and particle number correlate, but they come apart in common cases: insulin resistance, hypertriglyceridemia, small-dense LDL phenotypes. When they disagree, particle number wins on risk prediction.

Mendelian randomization studies — genetic variants that lower APOB from birth — show a dose-dependent reduction in lifetime ASCVD risk, with APOB outperforming both LDL-C and non-HDL-C when all three are tested in the same model. That causal signal is why the 2019 ESC/EAS dyslipidemia guidelines elevated APOB to a recommended treatment target alongside LDL-C, particularly in mixed dyslipidemia, metabolic syndrome, and diabetes.

How it’s measured

Two methods. Direct serum immunoassay is the gold standard: standardized across labs, accurate at any triglyceride level, and typically $10–30 out of pocket in the US if your physician will order it or you self-order through a direct-to-consumer lab. The Sniderman estimator derives APOB from a standard lipid panel using non-HDL-C and triglycerides, costs nothing extra if you already have a panel, and tracks the direct assay closely under most conditions. Accuracy degrades at triglycerides above ~400 mg/dL — use the direct assay there.

Targets

Standard target for primary prevention: APOB below 80 mg/dL. Aggressive target for high-risk patients — established ASCVD, familial hypercholesterolemia, diabetes with additional risk factors: below 60 mg/dL. Population mean in US adults runs roughly 95–105 mg/dL, which means most adults sit above the optimal range, not within it. APOB rises through middle age in both sexes. Women generally run lower than men until menopause, then catch up over the following decade.

FAQ

Should I test APOB or LDL-C?

If you can get APOB, test APOB. It captures the same information as LDL-C plus the contribution of remnant and triglyceride-rich particles, and it doesn’t require fasting. If APOB isn’t accessible, a standard lipid panel with non-HDL-C is the next-best surrogate.

Is APOB or LDL-C a better treatment target?

APOB, when they disagree. In discordance analyses — typically people with insulin resistance, high triglycerides, or small-dense LDL — APOB predicts events better than LDL-C. When the two agree, either works. Major guidelines now list APOB as a co-equal or preferred target in mixed dyslipidemia.

What’s the Sniderman estimator and when should I trust it?

A regression formula that estimates APOB from non-HDL-C and triglycerides on a standard panel. It performs well across the typical adult range and is what powers our calculator. Accuracy falls off at triglycerides above ~400 mg/dL; in that range, use a direct immunoassay.

Does APOB matter if my LDL is already low?

Sometimes yes. People with metabolic syndrome can carry a normal LDL-C and an elevated APOB because their particles are small and cholesterol-depleted — many small particles, modest cholesterol cargo. The risk tracks the particle count, not the cargo. Test once to confirm concordance.

How fast does APOB respond to treatment?

Drug effects (statins, ezetimibe, PCSK9 inhibitors, bempedoic acid) are essentially complete within 4–6 weeks. Diet and weight-loss effects accumulate over months and scale with the magnitude of weight loss. Retest at 8–12 weeks after a stable intervention.

How we built this page

Each intervention carries two ranks. The evidence grade (A/B/C/D) is a calibrated read on study quality and replication against the rubric. The tier (S/A/B/C/D) is the all-things-considered recommendation, factoring cost, access, effort, and effect size on this specific biomarker. The two often disagree on purpose: PCSK9 inhibitors are A on evidence and B on recommendation because of cost; aerobic exercise is S on the VO2max page and B here because its direct APOB effect is small. Every entry has a provenance block recording what was checked, by whom, and against which sources. See /methodology for the full rubric and the per-biomarker research log.

Tier list

S
High-Intensity Statin A
A
Ezetimibe A Bempedoic Acid B Mediterranean Diet A Weight Loss A Soluble Fiber (Psyllium) B Plant Sterols and Stanols A
B
PCSK9 Inhibitor A Aerobic Exercise B
C
Red Yeast Rice C Berberine C
D
Niacin (Extended-Release) B
biomarkerbench.com

Tier = all-things-considered recommendation, factoring evidence, cost, access, effort. The letter on each chip is the underlying evidence grade.

Comparison

High-Intensity Statin

S
Evidence
A
% Effect
30-40%
Cost
low
Effort
low
Time
weeks
Who for
Elevated APOB, no statin intolerance

Ezetimibe

A
Evidence
A
% Effect
15-20%
Cost
low
Effort
low
Time
weeks
Who for
Add-on when statin alone insufficient, or statin-intolerant

Bempedoic Acid

A
Evidence
B
% Effect
9-13%
Cost
medium
Effort
low
Time
weeks
Who for
Statin-intolerant, or as add-on when LDL still elevated

Weight Loss

A
Evidence
A
% Effect
5-15%
Cost
low
Effort
high
Time
months
Who for
Overweight/obese (BMI ≥25), especially with metabolic syndrome

Plant Sterols and Stanols

A
Evidence
A
% Effect
5-8%
Cost
low
Effort
low
Time
weeks
Who for
Anyone with elevated APOB; commonly fortified spreads/yogurts

Mediterranean Diet

A
Evidence
A
% Effect
4-10%
Cost
medium
Effort
medium
Time
months
Who for
Anyone; especially elevated CV risk

Soluble Fiber (Psyllium)

A
Evidence
B
% Effect
3-7%
Cost
low
Effort
low
Time
weeks
Who for
Anyone; especially preceding meals; constipation co-benefit

PCSK9 Inhibitor

B
Evidence
A
% Effect
45-55%
Cost
high
Effort
low
Time
weeks
Who for
High-risk ASCVD, FH, or statin-intolerant with persistent elevated APOB

Aerobic Exercise

B
Evidence
B
% Effect
1-3%
Cost
low
Effort
medium
Time
months
Who for
Everyone; ≥150 min/wk moderate or ≥75 min/wk vigorous

Red Yeast Rice

C
Evidence
C
% Effect
15-25%
Cost
low
Effort
low
Time
weeks
Who for
Statin-intolerant or statin-averse, willing to source standardized product

Berberine

C
Evidence
C
% Effect
5-12%
Cost
low
Effort
low
Time
weeks
Who for
Metabolic-syndrome populations; supplemental option, not primary

Niacin (Extended-Release)

D
Evidence
B
% Effect
10-20%
Cost
low
Effort
medium
Time
weeks
Who for
Not recommended for routine use given hard-outcome null + harm signal

Interventions

Each card shows the TL;DR. Expand sections for trial details, caveats, and references.

S

High-Intensity Statin

Evidence A 30-40% low cost

Anchor intervention. Multiple RCT generations across primary + secondary prevention. Rosuvastatin slightly edges atorvastatin on apoB head-to-head.

pharmacological · low effort · prescription · weeks to effect

Trial details & what to measure ▾

The trial that matters

No single trial — statins are the most replicated drug class in cardiology. The CTT collaboration meta-analyses pool ~170,000 patients across 26 RCTs and show ~22% MACE reduction per mmol/L LDL lowered. JUPITER (rosuvastatin 20 mg, primary prevention, elevated CRP) cut MACE by 44% over 1.9 years.

Real-world effect

High-intensity dosing (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) drops APOB roughly 30–40% and LDL ~50%. Rosuvastatin edges atorvastatin head-to-head on APOB (Adams 2014). VOYAGER documents wide inter-individual variability — some patients see >55% LDL drops, others <20% at the same dose.

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 30–40% reduction from baseline. If <25%, suspect adherence first, then consider low-responder status or switch agents (rosuvastatin if on atorvastatin).

Where it falls short

True intolerance is rarer than reported — placebo-controlled rechallenge trials show most “statin myalgia” is nocebo. But genuine myopathy exists, and statins modestly raise new-onset diabetes risk (~1 case per 255 patient-years on high-intensity). Avoid in pregnancy and active liver disease. Low-responders may need add-on ezetimibe or PCSK9 to hit APOB targets.

Risks & who it doesn't work for ▾

Risks: myalgia 5-10%; rare hepatotoxicity

Contraindications: pregnancy; active liver disease

Who it's for: Elevated APOB, no statin intolerance

A

Ezetimibe

Evidence A 15-20% low cost

Add-on to statin drops APOB another 10–15% and cuts MACE 6.4% in IMPROVE-IT. Modest effect, but the first non-statin LDL drug with hard-outcome proof.

pharmacological · low effort · prescription · weeks to effect

Trial details & what to measure ▾

The trial that matters

IMPROVE-IT (Cannon et al. 2015, NEJM 372:2387) randomized 18,144 post-ACS patients to simvastatin 40 mg ± ezetimibe 10 mg. Over 7 years, the ezetimibe arm hit lower LDL (~54 vs 70 mg/dL) and cut the primary MACE endpoint 6.4% (HR 0.936, 95% CI 0.89–0.99). First non-statin LDL-lowering drug to prove hard-outcome benefit.

Real-world effect

Monotherapy: APOB drops ~15–20% (Tremblay 2009 kinetics study: 19.8%). Add-on to statin: an additional ~10–15% APOB on top. The combo route is where ezetimibe earns its keep — adding it lets most patients hit aggressive APOB targets without escalating to PCSK9.

What to measure to confirm it’s working

Recheck APOB at 6–8 weeks. Add-on to existing statin: expect another 10–15% drop. Monotherapy: expect 15–20%. Sub-10% suggests poor adherence or low intestinal-absorption phenotype.

Where it falls short

Effect size is modest. Won’t get a high-APOB patient to target on its own. The 6.4% MACE RRR in IMPROVE-IT is real but small — clinical benefit is proportional to absolute LDL drop. Mild GI side effects in a minority. Combo-pill versions (statin+ezetimibe) help adherence but cost more than separate generics.

Risks & who it doesn't work for ▾

Risks: mild GI upset; rare myalgia

Contraindications: active liver disease (with statin)

Who it's for: Add-on when statin alone insufficient, or statin-intolerant

References (3) ▾
  1. Cannon et al. 2015, NEJM 372:2387. IMPROVE-IT — simvastatin ± ezetimibe in 18,144 post-ACS patients; MACE HR 0.936. [trial]
  2. Tremblay et al. 2009, PMC2694344. Ezetimibe + simvastatin on apoB metabolism in mixed hyperlipidemia (kinetics). [trial]
  3. Telford et al. 2007, ATVB. Effect of ezetimibe on in vivo kinetics of apoB-48 and apoB-100. [trial]
A

Bempedoic Acid

Evidence B 9-13% medium cost

For statin-intolerant patients, drops APOB 9–13% and cuts MACE 13% in CLEAR Outcomes. One landmark trial keeps it at evidence B until replicated; watch uric acid.

pharmacological · low effort · prescription · weeks to effect

Trial details & what to measure ▾

The trial that matters

CLEAR Outcomes (Nissen et al. 2023, NEJM 388:1353) randomized 13,970 statin-intolerant patients at high CV risk. Over 3.4 years bempedoic acid cut LDL 21% (~29 mg/dL) and reduced the 4-component MACE endpoint 13% (HR 0.87, 95% CI 0.79–0.96). MI fell 23%, coronary revascularization 19%. No mortality benefit.

Real-world effect

APOB drops 9–13% at 52 weeks (CLEAR Harmony, Ballantyne 2018). LDL ~21%. Effect is smaller than statins or PCSK9 — this is a third-line agent, not a replacement. Works in patients who genuinely cannot tolerate statins (the trial enriched for this).

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 10–13% reduction. Also check uric acid at baseline and at 3 months — bempedoic acid raises it.

Where it falls short

One landmark outcome trial → evidence grade B per the replication rule (waiting on a second). Hyperuricemia and gout flares are common enough to matter. Small tendon-rupture signal noted in the label. Effect size is modest relative to cost. If a patient tolerates any statin dose, that’s still the better lever.

Risks & who it doesn't work for ▾

Risks: hyperuricemia / gout flare; small tendon-rupture signal; modest LFT elevations

Contraindications: history of tendon rupture

Who it's for: Statin-intolerant, or as add-on when LDL still elevated

References (3) ▾
  1. Nissen et al. 2023, NEJM 388:1353. CLEAR Outcomes — bempedoic acid in 13,970 statin-intolerant patients; MACE HR 0.87. [trial]
  2. Ballantyne et al. 2018, CLEAR Harmony — apoB ↓9–12% sustained at 52 weeks on top of statin. [trial]
  3. Lincoff et al. 2024, Lancet Diabetes Endocrinol / JAHA. Prespecified diabetes and obesity subset analyses from CLEAR Outcomes. [trial]
A

Weight Loss

Evidence A 5-15% low cost

APOB drops roughly 1% per 1% body-weight lost in the 5–15% range; DiRECT shows 21% CV-outcome RRR at 10 years. Maintenance is the failure mode.

behavioral · high effort · lifestyle · months to effect

Trial details & what to measure ▾

The trial that matters

DiRECT (Lean et al. 2018, Lancet 391:541) used a structured total-diet-replacement program in primary care to drive ~10 kg weight loss in T2D patients. T2D remission was the headline endpoint, but the 10.2-year follow-up showed 21% RRR for CV outcomes. Confirms weight loss translates beyond biomarker improvement.

Real-world effect

APOB drops scale with the loss. Across hypoenergetic-diet studies, 6–12% body weight loss yields ~10–15% APOB reduction (Hayashi review). Desroches 2013: 10.2% weight loss plus Mediterranean diet cut LDL-apoB100 pool size 14.2%. Visceral fat loss matters more than total.

What to measure to confirm it’s working

Recheck APOB at 3–6 months, once weight has dropped ≥5%. Expect roughly 1% APOB drop per 1% body-weight loss in the 5–15% range. Plateau effect: maintenance keeps the gains; regain reverses them.

Where it falls short

Maintenance is the failure mode. Most unsupported weight loss is regained within 2–5 years, and APOB tracks back up. GLP-1 agonists have changed the cost/effort calculus but introduce their own dependencies. Below ~5% loss, APOB barely moves. Not a substitute for pharmacotherapy in high-APOB patients with established ASCVD risk.

Risks & who it doesn't work for ▾

Risks: muscle loss without resistance training; gallstones with rapid loss; nutrient gaps on very-low-calorie protocols

Contraindications: active eating disorder; underweight

Who it's for: Overweight/obese (BMI ≥25), especially with metabolic syndrome

References (3) ▾
  1. Lean et al. 2018, Lancet 391:541. DiRECT — primary-care total-diet-replacement program for T2D remission; CV outcomes at 10.2-yr follow-up. [trial]
  2. Hayashi et al., PMC6636168. Effects of weight change on apoB-containing emerging ASCVD risk factors — 6–12% weight loss → ~10–15% apoB drop. [review]
  3. Desroches et al. 2013, ATVB. 10.2% weight loss + Mediterranean diet reduced LDL-apoB100 pool size 14.2%. [trial]
A

Plant Sterols and Stanols

Evidence A 5-8% low cost

2 g/day cuts LDL ~10% and APOB ~5–8%. Well-replicated across 120+ RCTs; no hard-outcome trial.

supplement · low effort · otc · weeks to effect

Trial details & what to measure ▾

The trial that matters

Ras et al. 2014 (Br J Nutr) pooled 124 RCTs of plant sterol or stanol supplementation across doses of 0.6–3.3 g/day. LDL-C reduction ranged 6–12% in a clean dose-response. Katan et al. 2003 (Mayo Clin Proc) is the canonical earlier synthesis, anchoring the 2 g/day = ~10% LDL drop reference point.

Real-world effect

At 2 g/day, LDL-C drops ~10% and APOB ~5–8%. The APOB effect is slightly smaller than the LDL effect because the mechanism removes cholesterol cargo from particles before the particle count fully follows. Effect plateaus above ~2.5 g/day. Onset is 2–4 weeks.

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 5–8% reduction at 2 g/day. If unchanged, suspect inconsistent dosing — sterols work only when taken with fat-containing meals where cholesterol absorption is happening.

Where it falls short

No hard-outcome trial in 124 RCTs — every endpoint is a surrogate. Effect ceiling is low: even at maximal dose, APOB falls less than with the cheapest statin. Best used as a stack-layer for patients already on a statin who need an additional 5–8%, or for those who decline pharmacotherapy entirely. Skip in sitosterolemia.

Risks & who it doesn't work for ▾

Risks: modest reduction in fat-soluble vitamin and carotenoid absorption; very rare: worsened atherosclerosis in homozygous sitosterolemia

Contraindications: sitosterolemia

Who it's for: Anyone with elevated APOB; commonly fortified spreads/yogurts

References (2) ▾
  1. Katan et al. 2003, Mayo Clin Proc 78:965. Efficacy and safety of plant stanols and sterols in cholesterol management. [review]
  2. Ras et al. 2014, Br J Nutr. Dose-response meta-analysis of 124 plant sterol/stanol studies (0.6–3.3 g/d). [meta]
A

Mediterranean Diet

Evidence A 4-10% medium cost

Direct APOB drop is modest (4–10%), but PREDIMED and Lyon Diet Heart show ~30% CV-event RRR — the hard-outcome benefit exceeds what biomarker movement alone predicts.

behavioral · medium effort · lifestyle · months to effect

Trial details & what to measure ▾

The trial that matters

PREDIMED (Estruch et al., NEJM 2018 republication 378:e34) randomized 7,447 high-CV-risk Spaniards to Mediterranean + EVOO, Mediterranean + nuts, or low-fat advice. Over ~5 years both Mediterranean arms cut the primary composite CV endpoint ~30% (HR ~0.70). Lyon Diet Heart (de Lorgeril 1999) showed RR 0.27 for major cardiac events in secondary prevention.

Real-world effect

Direct APOB reduction is modest: ~4–10% (Solá 2011 trial of TMD+EVOO vs low-fat). The APOB/ApoA-I ratio improves more than absolute APOB. Hard-outcome benefit (~30% RRR) exceeds what the biomarker move alone predicts — suggesting non-lipid mechanisms (inflammation, endothelium) matter.

What to measure to confirm it’s working

Recheck APOB at 3–6 months. Expect 4–10% drop. Smaller moves are normal — the case for this diet rests on the hard-outcome trials, not the lipid response.

Where it falls short

Real-world adherence is the main failure mode — PREDIMED participants got dietitian support and free EVOO/nuts. Translating that to unsupported patients is harder. The republished PREDIMED corrected randomization issues but effect sizes held. Won’t replace a statin in a high-APOB patient; complements rather than substitutes.

Risks & who it doesn't work for ▾

Risks: weight gain if calorie-naive (EVOO + nuts are calorie-dense)

Contraindications: tree-nut allergy (substitute)

Who it's for: Anyone; especially elevated CV risk

References (3) ▾
  1. Estruch et al. 2018, NEJM 378:e34. PREDIMED republication — Mediterranean diet + EVOO or nuts; primary CV endpoint HR ~0.70. [trial]
  2. Solá et al. 2011, Atherosclerosis 218:174. Traditional Mediterranean diet RCT — apoB, apoA-I, and ratio. [trial]
  3. de Lorgeril et al. 1999, Circulation 99:779. Lyon Diet Heart final report — major cardiac events RR ~0.27 at 27 mo. [trial]
A

Soluble Fiber (Psyllium)

Evidence B 3-7% low cost

~10 g/day psyllium drops APOB ~3–7% (GRADE high). No hard-outcome trial — surrogate only — but cheap, safe, replicated.

supplement · low effort · otc · weeks to effect

Trial details & what to measure ▾

The trial that matters

Jovanovski et al. 2018 (Am J Clin Nutr 108:922) — systematic review and meta-analysis of 28 psyllium RCTs (n=1924, median 10.2 g/day). APOB reduced by 0.05 g/L (GRADE high-quality for the APOB endpoint specifically), LDL-C by 0.33 mmol/L. This is the strongest meta on a single, defined soluble fiber.

Real-world effect

At ~10 g/day psyllium, APOB drops 3–7% — modest but reliable. LDL-C drops ~7–8%. Effects appear within 4–8 weeks and are dose-dependent up to ~15 g/day. Whole-food sources (oats, beans, barley β-glucan) deliver similar but harder-to-titrate effects.

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 3–7% reduction at 10 g/day psyllium. If below 3%, suspect inconsistent dosing or that you’re already at an APOB-floor where fiber adds little.

Where it falls short

No hard-outcome trial — the entire case rests on surrogates. Adherence is the practical failure mode: a daily glass of gritty psyllium for a 5% APOB drop is a worse value proposition than a statin pill for 35%. Useful as a stack-layer or for statin-averse patients, not as a primary lever in anyone with substantially elevated APOB.

Risks & who it doesn't work for ▾

Risks: bloating and gas in the first 1–2 weeks; esophageal obstruction if taken dry without adequate water; may delay absorption of co-administered medications

Contraindications: esophageal stricture or swallowing disorder; bowel obstruction

Who it's for: Anyone; especially preceding meals; constipation co-benefit

References (2) ▾
  1. Jovanovski et al. 2018, Am J Clin Nutr 108:922. SR/MA of 28 psyllium RCTs (n=1924) on LDL-C, non-HDL-C, and apoB. [meta]
  2. Soluble fiber dose-response meta-analysis, 2023. ApoB MD −44.99 mg/L. [meta]
B

PCSK9 Inhibitor

Evidence A 45-55% high cost

Biggest APOB drop available — 45–55% on top of statin, with two independent RCTs (FOURIER, ODYSSEY) showing 15% MACE RRR. Tier B is about the $6k/yr price tag, not the evidence.

pharmacological · low effort · prescription · weeks to effect

Trial details & what to measure ▾

The trial that matters

FOURIER (Sabatine et al. 2017, NEJM 376:1713): evolocumab added to statin in 27,564 ASCVD patients drove LDL from 92 to 30 mg/dL (−59%) over 2.2 years and cut MACE 15% (HR 0.85, 95% CI 0.79–0.92). ODYSSEY OUTCOMES (alirocumab, n=18,924 post-ACS) replicated with HR 0.85. Two independent RCTs on hard outcomes — A-grade by the rubric.

Real-world effect

On top of a statin, APOB drops 43–52% (network meta-analysis, PMC9014015). LDL falls ~59%. Effect is consistent — far less inter-individual variability than statins. Patients on stable PCSK9 routinely see APOB <40 mg/dL.

What to measure to confirm it’s working

Recheck APOB at 4–8 weeks (effect plateaus fast). Expect ~50% reduction from on-statin baseline. Low responders are rare; flat APOB suggests injection-technique problems or missed doses.

Where it falls short

Cost. US list price ~$6,000/year keeps this off the table for most patients without ASCVD or familial hypercholesterolemia indication. Injection burden is small but real. No mortality benefit demonstrated in either landmark trial — the benefit is non-fatal MACE. Tier B here reflects the cost/access reality, not the evidence.

Risks & who it doesn't work for ▾

Risks: injection-site reactions; rare neurocognitive complaints (not confirmed in trials)

Contraindications: hypersensitivity to the monoclonal

Who it's for: High-risk ASCVD, FH, or statin-intolerant with persistent elevated APOB

References (4) ▾
  1. Sabatine et al. 2017, NEJM 376:1713. FOURIER — evolocumab in 27,564 ASCVD patients; MACE HR 0.85. [trial]
  2. Schwartz et al. 2018, NEJM 379:2097. ODYSSEY OUTCOMES — alirocumab post-ACS; MACE HR 0.85. [trial]
  3. Robinson et al. 2015, NEJM. ODYSSEY LONG TERM — alirocumab apoB reduction ~50% atop statin. [trial]
  4. Network meta-analysis of PCSK9i lipid effects, PMC9014015. ApoB reductions 43–52% atop statin. [meta]
B

Aerobic Exercise

Evidence B 1-3% low cost

Cardio moves APOB by only ~2 mg/dL on average — small for a biomarker that responds to drugs at 30–50%. The CV-mortality case for exercise is strong; the direct APOB case is not.

behavioral · medium effort · lifestyle · months to effect

Trial details & what to measure ▾

The trial that matters

Sarzynski et al. 2023 (Sports Med) pooled 57 RCTs of aerobic training (n=3194) using multivariate meta-analysis to read effects on APOB, non-HDL-C, and other novel lipid biomarkers. The APOB-specific result: −2.07 mg/dL, not statistically significant. Non-HDL-C and LDL-C moved more.

Real-world effect

Direct APOB reduction is ~1–3% on average — much smaller than what statins, ezetimibe, or even fiber deliver. The body-composition and insulin-sensitivity changes that follow sustained training amplify the lipid effect modestly, but the headline number on APOB itself stays small. Volume and intensity matter; sporadic activity does almost nothing.

What to measure to confirm it’s working

Recheck APOB at 12–16 weeks after establishing a stable program. Expect 1–3% reduction. If the goal is APOB, exercise alone will not move the needle — pair it with a pharmacological or dietary lever.

Where it falls short

The case for exercise rests on all-cause and CV mortality, not on APOB. Pure cardio in already lean, insulin-sensitive people barely touches the marker. Adding resistance training, weight loss, or dietary change amplifies the effect. On the VO2max page this intervention is S; here it is correctly B — same activity, different biomarker.

Risks & who it doesn't work for ▾

Risks: musculoskeletal injury in untrained starters; rare cardiac events in undiagnosed CAD during high-intensity onset

Contraindications: unstable angina; uncontrolled arrhythmia; decompensated heart failure

Who it's for: Everyone; ≥150 min/wk moderate or ≥75 min/wk vigorous

References (1) ▾
  1. Sarzynski et al. 2023, Sports Med. Multivariate meta-analysis of 57 RCTs (n=3194) of aerobic exercise on novel lipid biomarkers. [meta]
C

Red Yeast Rice

Evidence C 15-25% low cost

Standardized monacolin K (≤10 mg/d) cuts APOB ~20% — it is a statin. The catch: labeled products vary ~100-fold in actual content.

supplement · low effort · otc · weeks to effect

Trial details & what to measure ▾

The trial that matters

Cicero et al. 2021 (Front Pharmacol) — meta-analysis of 15 high-quality red yeast rice RCTs. APOB mean difference −27.98 mg/dL (95% CI −35.51 to −20.45). The 2020 JACC Focus Seminar by Banach et al. corroborates: LDL ↓15–25% at standardized monacolin K up to 10 mg/day.

Real-world effect

On a standardized 10 mg/day monacolin K product, LDL-C drops 15–25% and APOB ~20%. This is comparable to a low-to-moderate-intensity statin — because it pharmacologically is one. Onset is 4–6 weeks.

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 15–25% reduction on a standardized product. If unchanged, the most likely explanation is under-dosed monacolin in the specific product — not biological non-response.

Where it falls short

The product-quality problem is the whole story. Independent analyses have shown labeled monacolin content varies up to 100-fold across US supplements; citrinin (a nephrotoxic mycotoxin) contaminates a meaningful subset. The EU caps monacolin K at 3 mg/day, neutering the effect. No hard-outcome trial. For most patients seeking a statin-equivalent effect with statin risks, a generic statin is cheaper, safer, and regulated.

Risks & who it doesn't work for ▾

Risks: myalgia and myopathy (statin class effect); rare hepatotoxicity; citrinin contamination in poorly controlled products; 100-fold variability in actual monacolin content across labeled products

Contraindications: pregnancy; active liver disease; concurrent statin or strong CYP3A4 inhibitors

Who it's for: Statin-intolerant or statin-averse, willing to source standardized product

References (2) ▾
  1. Cicero et al. 2021, Front Pharmacol. Meta-analysis of 15 high-quality red yeast rice RCTs. ApoB MD −27.98 mg/dL. [meta]
  2. Banach et al. 2020, J Am Coll Cardiol 77:2070. JACC Focus Seminar on red yeast rice for hypercholesterolemia. [review]
C

Berberine

Evidence C 5-12% low cost

LDL drops ~12–15 mg/dL across meta-analyses; APOB-specific data is sparse and the trial base is mostly small Chinese metabolic-syndrome RCTs.

supplement · low effort · otc · weeks to effect

Trial details & what to measure ▾

The trial that matters

Lan et al. 2023 (J Diet Suppl 21:154) pooled 4,838 patients on berberine or berberine-containing combinations and found LDL-C mean difference −14.98 mg/dL. A 2024 50-RCT meta-analysis (n=4,150) corroborated at −0.30 mmol/L (−11.6 mg/dL). No meta isolates APOB cleanly — the APOB story is derived from the LDL signal.

Real-world effect

LDL drops ~10–15 mg/dL across trials; APOB-specific data is sparse but tracks proportionally, implying ~5–12% APOB reduction. Most of the effect is seen in metabolic-syndrome or T2D populations, where the AMPK arm of the mechanism contributes most. Onset is 4–8 weeks.

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 5–12% reduction. If unchanged, the result is plausibly genuine non-response — heterogeneity in trials is wide.

Where it falls short

The trial base is dominated by small Chinese RCTs in metabolic-syndrome populations, with quality concerns flagged in umbrella reviews. No hard-outcome trial exists. GI tolerability is the main practical limit. CYP3A4 inhibition is meaningful — check medication interactions before stacking. For most patients seeking 10% LDL movement, a low-dose statin is cheaper, better-evidenced, and better-tolerated.

Risks & who it doesn't work for ▾

Risks: GI upset (constipation, diarrhea, cramping) — common; drug interactions via CYP3A4 and P-glycoprotein inhibition; transient transaminase elevations

Contraindications: pregnancy and lactation (kernicterus risk in neonates); concurrent cyclosporine, tacrolimus, or other narrow-window CYP3A4 substrates

Who it's for: Metabolic-syndrome populations; supplemental option, not primary

References (3) ▾
  1. Lan et al. 2023, J Diet Suppl 21:154. Pooled analysis of berberine on lipids (n≈4838). LDL-C MD −14.98 mg/dL. [meta]
  2. Ju et al. 2018, SR/MA of berberine RCTs for dyslipidaemias. [meta]
  3. 2024 meta-analysis of 50 berberine RCTs (n=4150). LDL-C MD −0.30 mmol/L. [meta]
D

Niacin (Extended-Release)

Evidence B 10-20% low cost

APOB drops 10–20% on niacin — but two large modern RCTs (AIM-HIGH, HPS2-THRIVE) found zero MACE benefit on top of a statin and serious harms. The biomarker moved; outcomes didn't.

pharmacological · medium effort · prescription · weeks to effect

Trial details & what to measure ▾

The trial that matters

HPS2-THRIVE (NEJM 2014, n=25,673) tested ER niacin + laropiprant on top of a statin in high-risk patients. Primary vascular event rate: 13.2% niacin vs 13.7% placebo (NS). The earlier AIM-HIGH trial (NEJM 2011, n=3,414) was stopped early for futility — niacin on top of simvastatin produced no MACE benefit despite moving lipids in the expected direction.

Real-world effect

APOB drops 10–20% on ER niacin at ≥1 g/day, LDL ~15%, HDL +20%. The biomarker response is genuine and reproducible. That is precisely the problem: the surrogate moves, but two large modern trials show no patient benefit.

What to measure to confirm it’s working

Recheck APOB at 8–12 weeks. Expect 10–20% reduction at ≥1 g/day ER niacin. But “working on the biomarker” is not the same as “preventing events” — see below.

Where it falls short

This is the entire reason niacin is on this page. AIM-HIGH and HPS2-THRIVE are the cleanest “biomarker moved, outcomes didn’t” pair in modern cardiology. HPS2-THRIVE went further and documented significant harm: excess new-onset diabetes, serious infection, GI and intracranial bleeding, and myopathy. Older positive data (Coronary Drug Project, 1975/1986) predates statins and has never been replicated in a statin-treated population. The mechanistic story for HDL-raising lipid drugs broadly — niacin, CETP inhibitors — has not produced outcome wins. Niacin is the rubric’s teaching example: an evidence-B biomarker effect, correctly de-emphasized to tier D on the all-things-considered call, because the question that matters is not “does APOB move?” but “do events follow?” Here they don’t, and the side-effect ledger is real. Do not use routinely.

Risks & who it doesn't work for ▾

Risks: flushing (common, dose-limiting); new-onset diabetes (HPS2-THRIVE); GI bleeding and intracranial bleeding (HPS2-THRIVE); serious infection (HPS2-THRIVE); myopathy, especially combined with statin (HPS2-THRIVE); hepatotoxicity, more with sustained-release preparations; hyperuricemia and gout flares

Contraindications: active liver disease or unexplained transaminase elevation; active peptic ulcer disease; active arterial bleeding

Who it's for: Not recommended for routine use given hard-outcome null + harm signal

References (3) ▾
  1. AIM-HIGH Investigators 2011, NEJM 365:2255. Niacin in patients with low HDL on statin. Stopped early for futility. [trial]
  2. HPS2-THRIVE Collaborative Group 2014, NEJM 371:203. Niacin/laropiprant + statin (n=25,673). No MACE benefit; excess diabetes, infection, bleeding, myopathy. [trial]
  3. Coronary Drug Project, 1975/1986. Pre-statin-era niacin monotherapy; 15-yr mortality benefit not replicated in modern statin-treated trials. [trial]

Methodology & notes